Lannett will receive finished product from Banner Pharmacaps, under a previously announced supply agreement. Banner received approval from the FDA of its abbreviated new drug application last week for Amantadine Hydrochloride soft gel capsules USP 100mg, the generic equivalent of USL Pharma’s Symmetrel.
Amantadine Hydrochloride soft gel capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Arthur Bedrosian, president and CEO of Lannett, said: “Amantadine is an important addition to our portfolio and represents the second product for Lannett resulting from strategic alliances formed in the past few years.”